The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus

Nat Clin Pract Endocrinol Metab. 2008 May;4(5):240-1. doi: 10.1038/ncpendmet0783. Epub 2008 Mar 4.

Authors

Marc Y Donath¹, Thomas Mandrup-Poulsen

Affiliation

¹ Clinic for Endocrinology and Diabetes, University Hospital Zurich and Center for Integrated Human Physiology, University of Zurich, Switzerland.

PMID: 18317479
DOI: 10.1038/ncpendmet0783

No abstract available

MeSH terms

Adipokines / blood
C-Reactive Protein / analysis
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / metabolism
Glycated Hemoglobin / analysis
Humans
Injections, Subcutaneous
Insulin / blood
Insulin Resistance / physiology
Insulin-Secreting Cells / drug effects
Insulin-Secreting Cells / metabolism
Interleukin 1 Receptor Antagonist Protein / administration & dosage*
Interleukin-6 / blood
Proinsulin / blood
Randomized Controlled Trials as Topic
Receptors, Interleukin-1 / antagonists & inhibitors*

Substances

Adipokines
Glycated Hemoglobin A
Insulin
Interleukin 1 Receptor Antagonist Protein
Interleukin-6
Receptors, Interleukin-1
C-Reactive Protein
Proinsulin